Horizon Therapeutics Public Company Stock News

Horizon Therapeutics (HZNP) said a new analysis showed that Uplizna reduced the severity of attacks and levels of key disease-related biomarkers in people with Neuromyelitis…

CHICAGO , Feb. 15, 2022 /PRNewswire-PRWeb/ -- Harmony 4 Hope, a non-profit organization merging music and storytelling to provide funding for the research of rare diseases, is teaming up with Grammy Award winner and NYT Best Selling Author Peter Frampton to raise awareness for rare disease. Together with the Genomic Sciences and Precision Medicine Center at the Medical College of Wisconsin , Children''s Hospital of Wisconsin , Johns Hopkins Medicine , and sponsor Horizon Therapeutics , Harmony 4 Hope is proud to welcome Peter Frampton as a guest at their upcoming Rare Storytellers event as he shares his story of living with Inclusion Body Myositis and his diagnostic journey. "We could not be more pleased to welcome Peter Frampton as a Rare Storyteller," said Kerry Hughes , Executive Director of Harmony 4 Hope. "Rare Storytellers is a rapidly growing network of patients, musicians and medical professionals currently representing over 30 rare diseases. Adding a strong voice like Peter Frampton''s shows just how impactful these diseases are, and how critical the research being done to cure them is." Peter Frampton , …

An analysis conducted by Horizon Therapeutics (HZNP) on hearing-related adverse events associated with Tepezza found that they were at a rate similar to that seen in clinical studies.

Horizon Therapeutics is now on board ahead of this summers iteration at Mount Juliet

Dublin-based global biotechnology company Horizon Therapeutics will take over from Dubai Duty Free as title sponsors off the Irish Open in a six-year deal.

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Horizon Therapeutics: Powerful Pharma Player On Long-Term Growth Track

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appea

Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming virtual investor conferences: Goldman Sachs 14th Annual Hea

(RTTNews) - Alpine Immune Sciences, Inc. (ALPN) and Horizon Therapeutics plc (HZNP) announced a license and collaboration agreement for the development and commercialization of up to four preclinical candidates generated from Alpine''s discovery platform. The agreement includes licensing of a lead, potential first-in-class preclinical candidate,

Kirr Marbach & Co. LLC IN raised its position in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 2.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 94,733 shares of the biopharmaceutical companys stock after buying an additional 2,156 shares during the period. Horizon Therapeutics Public comprises approximately []